Q-omics provides the consensus-scored ZNF319 profile across patient tissues and cancer cell-line models. ZNF319 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF319 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF319 RNA expression shows 19,967 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where ZNF319 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF319 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF319 survival associations across molecular data types. ZNF319 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF319 RNA expression–survival associations across cancer types. High ZNF319 expression shows unfavorable associations in CESC, BLCA, LIHC and LUAD, but favorable associations in KIRC and SCLC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF319 RNA expression.
This table summarizes ZNF319 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF319. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF319 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRP, LIHC, COAD and BLCA. The HNSC box plot shows higher ZNF319 RNA expression in tumor versus normal tissue (log2 FC = +1.537, t-test p < 0.001).
This table shows molecular features associated with ZNF319 in patient tissues and cancer cell lines. In patient samples, ZNF319 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF319 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
